X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NLS Pharmaceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2020
Details:
NLS-2 (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: NLS-2
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
Quilience (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Quilience® (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Quilience® (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) which is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist which is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
Quilience® (mazindol ER) is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist. It is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Quilience (Mazindol ER), the Company's lead product candidate and proprietary extended-release formulation of Mazindol (Mazindol ER), is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH).
Lead Product(s): Mazindol
Therapeutic Area: Psychiatry/Psychology Product Name: Nolazol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Quilience®, is a proprietary extended-release formulation of Mazindol (mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH).
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 14, 2022
Details:
NLS intends to use the net proceeds from the offering to accelerate the ongoing clinical development of its lead product, Quilience® (mazindol ER) for the treatment of narcolepsy, to advance NLS-4 and other product candidates.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners L.P.
Deal Size: $70.6 million Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2022
Details:
Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH).
Lead Product(s): Mazindol
Therapeutic Area: Psychiatry/Psychology Product Name: Quilience
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
The NPP will provide access to Quilience® having Mazindol ER for the treatment of IH where this medication would not otherwise be available for this indication in certain countries.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2022
Details:
Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH).
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Quilience®, is proprietary extended-release formulation of Mazindol (Mazindol ER), for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia (IH).
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
NLS intends to use the net proceeds from the offering to fund the ongoing development of its lead product, Quilience® (Mazindol ER) for the treatment of narcolepsy, to support business development and licensing activities, and for general corporate purposes.
Lead Product(s): Mazindol
Therapeutic Area: Sleep Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laidlaw & Company
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 03, 2022
Details:
Agreement provides exclusive rights to all available data included in the original new drug application for mazindol in the U.S. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, used for to treat narcolepsy in compassionate use programs.
Lead Product(s): Mazindol
Therapeutic Area: Psychiatry/Psychology Product Name: Quilience
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NLS Pharmaceutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Adare has been transforming oral delivery challenges into proprietary product solutions.
